Prof. Dr. med. Marc O. Schurr, founder of Ovesco, appointed Senior Advisor to Tübingen-based SHS
Effective October 1, 2020, Tübingen-based medtech investor SHS has appointed Prof. Marc O. Schurr, founder and Executive Board member of Ovesco AG, as Senior Advisor Schurr, a successful medtech entrepreneur and professor of experimental medicine and medical technology, understands what matters when it comes to clinical approvals and regulatory processes In Schurr, SHS gains a […]
SHS invests in Salvia BioElectronics B.V.
Salvia BioElectronics raises EUR 26M (USD 31M) to develop innovative neurostimulation therapy for chronic migraine Series A led by new investors Panakès Partners, INKEF Capital and SHS Gesellschaft für Beteiligungsmanagement Eindhoven, the Netherlands, September 22, 2020 – Salvia BioElectronics B.V., a neurostimulation platform company targeting chronic migraine, today announced it has raised EUR 26M in […]
Miracor Medical raises 24M€
Our portfolio company Miracor raised 24m EUR to fund three clinical trials, totaling 750 patients, and start commercialization of its PiCSO therapy. The PiCSO therapy reduces infarct sizes and therefore mortality and hospitalization of patients suffering from ST-elevated myocardial infarction (STEMI).
Frankfurter Allgemeine Zeitung: „Schnäppchen in der Medizintechnik“ (Bargains in medical technology)
The FAZ published a background article on the active M&A environment in medtech despite (and partially even supported by) the market conditions with a specific focus on the Siemens Healthineers / Varian Medical Systems transaction. Hubertus Leonhardt, managing partner of SHS, has been quoted regarding the current pricing in M&A transactions for healthcare companies.
Schwäbische Zeitung: “SHS-Medizintechnikindex nimmt Branche unter die Lupe” (SHS Medical Technology Index takes a close look at the industry)
How has the medical technology industry developed in comparison to the overall economy in recent years? The Schwäbische Zeitung (https://www.schwaebische.de) reports on the SHS Medical Technology Index.
Trend reversal: SHS Medical Technology Index points upwards again
SHS sees medical technology back on track for success in Germany in 2019 Medical technology sector increases turnover by 10% in 2019 In spite of COVID-19, SHS expects the medical technology industry to outperform the German economy as a whole in 2020 as well Effects of the EU Medical Device Regulation (MDR) not yet digested […]
Ärzteblatt: “NMR-Spektroskopie: Abstoßung ohne Biopsie erkennen” (NMR spectroscopy: detecting rejection without biopsy)
A real improvement in kidney transplant rejection diagnostics: The transplantation of a organ (e.g. kidney) is a highly invasive procedure, a high risk but also chance for the patient and a huge burden for the body to process. Furthermore, current standards of diagnosis for the rejection risk of transplanted kidneys are invasive, not robust, and an additonal burden for the patient. This is changing now by using NMR spectroscopy as a reliable and cost efficient non invasive alternative. Would it not be good to have access to such methodology as a standard?
medtech zwo: “MedtecLIVE Session: Finanzierung in der Medizintechnik”
At MedtecLIVE, which will take place virtually for the first time on 1 July, everything will revolve around the topic of financing in medical technology, with the aim of networking the players in the medical technology sector. The programme includes live streamed lectures, talks and pitches. Among others, SHS will also be present.
SHS appoints Heinz Jacqui Senior Advisor
Heinz Jacqui (59) has been appointed Senior Advisor at SHS Gesellschaft für Beteiligungsmanagement effective June 1, 2020. By way of succession arrangements or growth financing, SHS specializes in investing in innovative healthcare companies that focus on medical technology and the life sciences. Through several funds, SHS has more than EUR 300 million under management. It […]
Miracor Medical’s PiCSO® System receives CE Mark
Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system features improvements in ease of use.